Based on the successful demonstration of the potential targeted-PDT of PSMA-YI-1 NPs in bladder cancer cells, the additional loading of chemo-drugs into the PSMA nanocarriers may result in better anticancer efficacy with lower dose administration for future chemotherapeutic strategies. The gene discussed is FOLH1; the disease is urinary bladder cancer.